Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SLV026
MIFTS: 56

Salivary Gland Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Salivary Gland Carcinoma

About this section

MalaCards integrated aliases for Salivary Gland Carcinoma:

Name: Salivary Gland Carcinoma 12 15
Salivary Gland Cancer 12 38 56 44 15
Malignant Tumor of the Major Salivary Gland 12
Malignant Neoplasm of Major Salivary Gland 12
Malignant Neoplasm of Salivary Gland Duct 12
Malignant Tumor of the Salivary Gland 12
Malignant Neoplasm of Salivary Gland 12
Major Salivary Gland Carcinoma 17

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Oral diseases Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:0050904 DOID:8850
KEGG 38 H01508
ICD9CM 36 142.8
ICD10 34 C08
UMLS 74 C0153362
Sources

Summaries for Salivary Gland Carcinoma

About this section
MedlinePlus : 44 Your salivary glands make saliva - sometimes called spit - and empty it into your mouth through openings called ducts. Saliva makes your food moist, which helps you chew and swallow. It helps you digest your food. It also cleans your mouth and contains antibodies that can kill germs. Salivary gland cancer is a type of head and neck cancer. It is rare. It may not cause any symptoms, or you could notice A lump in your ear, cheek, jaw, lip, or inside the mouth Fluid draining from your ear Trouble swallowing or opening the mouth widely Numbness, weakness, or pain in your face Doctors diagnose salivary gland cancer using a physical exam, imaging tests, and a biopsy. Treatment can include surgery, radiation therapy, and/or chemotherapy. NIH: National Cancer Institute

MalaCards based summary : Salivary Gland Carcinoma, also known as salivary gland cancer, is related to adenoid cystic carcinoma and mucoepidermoid carcinoma. An important gene associated with Salivary Gland Carcinoma is MAML2 (Mastermind Like Transcriptional Coactivator 2), and among its related pathways/superpathways are Notch signaling pathway and PI3K-Akt signaling pathway. The drugs Iodine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, testes and brain, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An oral cavity cancer that is located in the salivary gland.

Sources

Related Diseases for Salivary Gland Carcinoma

About this section

Diseases in the Salivary Gland Carcinoma family:

Salivary Gland Cancer, Adult

Diseases related to Salivary Gland Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 adenoid cystic carcinoma 32.3 CYLD KIT KRT7 NFIB
2 mucoepidermoid carcinoma 31.4 CRTC1 CRTC3 EGFR KRT7 MAML2
3 salivary gland cancer, adult 12.6
4 salivary gland cancer, childhood 12.3
5 brooke-spiegler syndrome 11.3
6 sublingual gland cancer 11.2
7 parotid gland cancer 11.2
8 malignant peritoneal mesothelioma 10.4 CDKN2A EGFR
9 deafness, autosomal recessive 39 10.4 HGF MET
10 infiltrating angiolipoma 10.4 CDKN2A MDM2
11 anaplastic oligodendroglioma 10.4 CDKN2A EGFR
12 deafness, autosomal recessive 97 10.4 HGF MET
13 acral lentiginous melanoma 10.4 CDKN2A KIT MET
14 benign breast adenomyoepithelioma 10.4 EGFR KRT7
15 inverted transitional papilloma 10.4 CDKN2A KRT7
16 fibrosarcoma of bone 10.4 CDKN2A KIT MDM2
17 ceruminoma 10.4 KIT KRT7
18 doxorubicin induced cardiomyopathy 10.4 EGFR HGF MET
19 grade iii astrocytoma 10.4 CDKN2A EGFR MDM2
20 nervous system cancer 10.4 CDKN2A EGFR MDM2
21 endometrial squamous cell carcinoma 10.4 CDKN2A HGF MET
22 familial renal papillary carcinoma 10.4 EGFR HGF MET
23 central nervous system melanocytic neoplasm 10.3 CDKN2A HGF KIT
24 spinal chordoma 10.3 EGFR HGF MET
25 jejunal cancer 10.3 KIT KRT7
26 central nervous system cancer 10.3 CDKN2A EGFR SOX2
27 respiratory system cancer 10.3 CDKN2A EGFR MET
28 li-fraumeni syndrome 10.3 CDKN2A EGFR MDM2
29 cellular schwannoma 10.3 CDKN2A MDM2 SOX2
30 ocular cancer 10.3 CDKN2A MDM2 SOX2
31 oncocytic breast carcinoma 10.3 EGFR KRT7
32 lacrimal system cancer 10.3 MAML2 NFIB
33 adenosquamous carcinoma 10.3 EGFR KIT KRT7
34 anus basaloid carcinoma 10.3 CYLD KRT7
35 conventional fibrosarcoma 10.3 KIT MDM2
36 lacrimal gland mucoepidermoid carcinoma 10.3 CRTC1 MAML2
37 adenoid basal cell carcinoma 10.3 CDKN2A KIT KRT7
38 large cell neuroendocrine carcinoma 10.3 EGFR KIT KRT7
39 basaloid squamous cell carcinoma 10.3 CDKN2A EGFR KRT7
40 vulva cancer 10.3 CDKN2A EGFR KRT7
41 mucinous adenocarcinoma 10.3 CDKN2A EGFR KRT7
42 well-differentiated liposarcoma 10.3 CDKN2A KRT7 MDM2
43 malignant peripheral nerve sheath tumor 10.3 CDKN2A EGFR KIT MDM2
44 intratubular embryonal carcinoma 10.3 KIT KRT7
45 large cell medulloblastoma 10.3 HGF MET
46 breast mucoepidermoid carcinoma 10.3 CRTC1 MAML2
47 middle ear adenoma 10.2 ISL1 KRT7
48 cribriform carcinoma 10.2 KIT KRT7
49 supratentorial cancer 10.2 CDKN2A EGFR MDM2 SOX2
50 cerebrum cancer 10.2 CDKN2A EGFR MDM2 SOX2

Graphical network of the top 20 diseases related to Salivary Gland Carcinoma:



Diseases related to Salivary Gland Carcinoma
Sources

Symptoms & Phenotypes for Salivary Gland Carcinoma

About this section

GenomeRNAi Phenotypes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.66 EGFR
2 Decreased viability GR00221-A-1 9.66 CDKN2A CYLD EGFR HGF KIT SOX2
3 Decreased viability GR00221-A-2 9.66 CYLD HGF
4 Decreased viability GR00221-A-3 9.66 CDKN2A
5 Decreased viability GR00221-A-4 9.66 CDKN2A EGFR HGF SOX2
6 Decreased viability GR00301-A 9.66 CYLD KIT
7 Decreased viability GR00402-S-2 9.66 CDKN2A CYLD EGFR HGF KIT SOX2

MGI Mouse Phenotypes related to Salivary Gland Carcinoma:

47 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.43 ALKBH1 ALKBH3 CDKN2A CRTC3 CYLD EGFR
2 homeostasis/metabolism MP:0005376 10.4 ALKBH3 CDKN2A CRTC1 CRTC3 CYLD EGFR
3 growth/size/body region MP:0005378 10.38 ALKBH1 CDKN2A CRTC1 CRTC3 CYLD EGFR
4 endocrine/exocrine gland MP:0005379 10.29 ALKBH1 CDKN2A CRTC1 CYLD EGFR ISL1
5 mortality/aging MP:0010768 10.29 ALKBH1 ALKBH3 CDKN2A CRTC3 CYLD EGFR
6 cardiovascular system MP:0005385 10.24 ALKBH1 CDKN2A EGFR HGF ISL1 KIT
7 digestive/alimentary MP:0005381 10.22 CDKN2A CYLD EGFR ISL1 KIT MDM2
8 embryo MP:0005380 10.21 ALKBH1 CDKN2A EGFR HGF ISL1 KIT
9 limbs/digits/tail MP:0005371 10.21 ALKBH1 CRTC3 CYLD EGFR ISL1 KIT
10 craniofacial MP:0005382 10.18 ALKBH1 EGFR ISL1 KIT MDM2 MET
11 muscle MP:0005369 10.06 CDKN2A CRTC3 EGFR ISL1 KIT MDM2
12 liver/biliary system MP:0005370 10.04 CDKN2A CRTC3 EGFR HGF KIT MDM2
13 neoplasm MP:0002006 10.03 CDKN2A CYLD EGFR ISL1 KIT MDM2
14 no phenotypic analysis MP:0003012 10.01 CDKN2A EGFR HGF ISL1 KIT MDM2
15 normal MP:0002873 9.97 ALKBH3 CYLD EGFR ISL1 KIT MDM2
16 renal/urinary system MP:0005367 9.8 EGFR ISL1 KIT KRT7 MDM2 MET
17 pigmentation MP:0001186 9.72 CDKN2A EGFR KIT MDM2 SOX2
18 respiratory system MP:0005388 9.7 CDKN2A CYLD EGFR KIT MET NFIB
19 skeleton MP:0005390 9.65 ALKBH1 CDKN2A CRTC3 EGFR ISL1 KIT
20 vision/eye MP:0005391 9.28 ALKBH1 CDKN2A EGFR ISL1 KIT MET
Sources

Drugs & Therapeutics for Salivary Gland Carcinoma

About this section

Drugs for Salivary Gland Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 236)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 3 7553-56-2 807
2
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 441203 84093 2767
3
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 33069-62-4 36314
5
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
6
Fluorouracil Approved Phase 3,Phase 1 51-21-8 3385
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
8
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Promethazine Approved, Investigational Phase 3 60-87-7 4927
11
Histamine Approved, Investigational Phase 3 51-45-6 774
12
Doxepin Approved, Investigational Phase 3 1668-19-5 667468 667477
13
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
14
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
15
leucovorin Approved Phase 3,Phase 1 58-05-9 6006 143
16
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
17
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1 59-30-3 6037
19 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
20 cadexomer iodine Phase 3
21 Pharmaceutical Solutions Phase 3,Phase 2
22 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
23 Immunologic Factors Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
24 Antimitotic Agents Phase 3,Phase 1,Phase 2,Not Applicable
25 Antimetabolites Phase 3,Phase 1,Phase 2
26 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Early Phase 1
27 Peripheral Nervous System Agents Phase 3,Phase 2
28 Neurotransmitter Agents Phase 3,Phase 2
29 Autonomic Agents Phase 3,Phase 2
30 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
31 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Dermatologic Agents Phase 3,Phase 2
33 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2,Not Applicable
34 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2,Not Applicable
35 Mitogens Phase 3,Phase 2,Phase 1
36 Antibodies Phase 3,Phase 1,Phase 2
37 Endothelial Growth Factors Phase 3,Phase 1
38 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
39 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2
40 Immunoglobulin G Phase 3
41 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1,Not Applicable
42 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
43 Immunoglobulins Phase 3,Phase 1,Phase 2
44 Cholinergic Agents Phase 3,Phase 2
45 Muscarinic Agonists Phase 3,Phase 2
46 Analgesics Phase 3,Phase 2
47 Adjuvants, Anesthesia Phase 3
48 Anesthetics, General Phase 3
49 Anesthetics Phase 3
50 Anesthetics, Intravenous Phase 3

Interventional clinical trials:

(show top 50) (show all 197)
# Name Status NCT ID Phase Drugs
1 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
2 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
3 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
4 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
5 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
6 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
9 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
10 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
11 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
12 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
13 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
14 Activity of Sorafenib in Salivary Gland Cancer Unknown status NCT01703455 Phase 2 Sorafenib
15 Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck Unknown status NCT02558387 Phase 2 BIBF1120
16 Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers Unknown status NCT02867852 Phase 2 Abiraterone acetate
17 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
18 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
19 Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy Unknown status NCT00003856 Phase 2 temoporfin
20 Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
21 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
22 CO(Mbined Therapy of Malignant) S(Alivary Gland tu)M(Ours With)I(MRT and) c(Arbon Ions): COSMIC Unknown status NCT01154270 Phase 2
23 Iressa Study in Patients With Salivary Gland Cancer Completed NCT00509002 Phase 2 Gefitinib
24 A Phase I/II Trial of APG-115 in Patients With Salivary Gland Carcinoma Not yet recruiting NCT03781986 Phase 1, Phase 2 APG115 mono-therapy;APG115 + Carboplatin
25 Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck Active, not recruiting NCT03132038 Phase 2 Nivolumab
26 Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma Active, not recruiting NCT02393820 Phase 2 pazopanib
27 A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
28 Cabozantinib in Advanced Salivary Gland Cancer Patients Recruiting NCT03729297 Phase 2 Cabozantinib
29 Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14 Active, not recruiting NCT02860936 Phase 2 Lenvatinib
30 Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer Completed NCT01613768 Phase 2 eribulin mesylate
31 Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Completed NCT00045669 Phase 2 imatinib mesylate
32 Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14 Active, not recruiting NCT02857712 Phase 2 Axitinib
33 Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Terminated NCT00126607 Phase 2
34 Androgen Deprivation Therapy in Advanced Salivary Gland Cancer Recruiting NCT01969578 Phase 2 bicalutamide + triptorelin;Cisplatin + Doxorubicin;Carboplatin + Paclitaxel
35 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2 Trastuzumab
36 Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers Recruiting NCT03749460 Phase 1, Phase 2
37 A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT01678105 Phase 2 Dovitinib
38 Title XELOX FOR SALIVARY GLAND CANCERS Terminated NCT00101075 Phase 2 Capecitabine;Oxaliplatin
39 Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Recruiting NCT03172624 Phase 2 Nivolumab;Ipilimumab
40 Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Active, not recruiting NCT02538510 Phase 1, Phase 2 Vorinostat
41 Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Completed NCT00002632 Phase 2 paclitaxel
42 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2 lapatinib ditosylate
43 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
44 Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer Recruiting NCT03146650 Phase 2
45 Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors Recruiting NCT03360890 Phase 2 Pembrolizumab;Docetaxel
46 Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma Completed NCT00228488 Phase 2 Gefitinib
47 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Completed NCT00859937 Phase 2 Dasatinib
48 Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies Withdrawn NCT00984217 Phase 2 Panitumumab
49 Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies Withdrawn NCT01634880 Phase 2 Postoperative Radiotherapy and Panitumumab
50 Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers Active, not recruiting NCT02749903 Phase 2 enzalutamide

Search NIH Clinical Center for Salivary Gland Carcinoma

Sources

Genetic Tests for Salivary Gland Carcinoma

About this section
Sources

Anatomical Context for Salivary Gland Carcinoma

About this section

MalaCards organs/tissues related to Salivary Gland Carcinoma:

42
Salivary Gland, Testes, Brain, Lymph Node, Thyroid, Kidney, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Salivary Gland Carcinoma:

20
The Salivary Gl
Sources

Publications for Salivary Gland Carcinoma

About this section

Articles related to Salivary Gland Carcinoma:

(show top 50) (show all 258)
# Title Authors Year
1
The limited role of elective neck dissection in patients with cN0 salivary gland carcinoma. ( 30528947 )
2019
2
Contemporary treatment patterns and outcomes of salivary gland carcinoma: a National Cancer Database review. ( 30649610 )
2019
3
High metastatic node number, not extranodal extension, as a node-related prognosticator in surgically treated patients with nodal metastatic salivary gland carcinoma. ( 30652371 )
2019
4
New approaches in salivary gland carcinoma. ( 30844885 )
2019
5
External beam radiotherapy for the treatment of feline salivary gland carcinoma: six new cases and a review of the literature. ( 29767566 )
2019
6
Impact of tumour profiling on clinical trials in salivary gland cancer. ( 30102009 )
2019
7
Survival and characteristics of pediatric salivary gland cancer: A systematic review and meta-analysis. ( 30378272 )
2019
8
Impact of treating facilities' type and volume in patients with major salivary gland cancer. ( 30698823 )
2019
9
Uptake of 18F-Fluorodeoxyglucose in Major Salivary Gland Cancer Predicts Survival Adjusting for Pathological Stage. ( 30711993 )
2019
10
Examined and positive lymph nodes counts and lymph nodes ratio are associated with survival in major salivary gland cancer. ( 30905082 )
2019
11
Development of a novel salivary gland cancer lymph node staging system. ( 29742277 )
2018
12
Stromal collagen type VI associates with features of malignancy and predicts poor prognosis in salivary gland cancer. ( 29949051 )
2018
13
AAA+ ATPases Reptin and Pontin as potential diagnostic and prognostic biomarkers in salivary gland cancer - a short report. ( 29873033 )
2018
14
Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. ( 29044862 )
2018
15
Treatment outcomes in metastatic and localized high-grade salivary gland cancer: high chance of cure with surgery and post-operative radiation in T1-2A N0 high-grade salivary gland cancer. ( 29925355 )
2018
16
Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. ( 29555661 )
2018
17
Treatment Times in Salivary Gland Cancer: National Patterns and Association with Survival. ( 29460669 )
2018
18
Salivary gland carcinoma: Prediction of cancer death risk based on apparent diffusion coefficient histogram profiles. ( 29975742 )
2018
19
Prognostic value of primary tumor surgery in minor salivary-gland carcinoma patients with distant metastases at diagnosis: first evidence from a SEER-based study. ( 30050326 )
2018
20
Pretreatment Primary Tumor and Nodal SUVmax Values on 18F-FDG PET/CT Images Predict Prognosis in Patients With Salivary Gland Carcinoma. ( 30273205 )
2018
21
Pre-treatment metabolic tumor volume predicts tumor metastasis and progression in high-grade salivary gland carcinoma. ( 30293119 )
2018
22
ELMO3 - a Negative Prognostic Marker in Minor Salivary Gland Carcinoma. ( 30374620 )
2018
23
Significant prognostic factors affecting treatment outcomes of salivary gland carcinoma: a multicenter retrospective analysis. ( 28936637 )
2018
24
Second primary cancer after major salivary gland carcinoma. ( 28960648 )
2018
25
Minor Salivary Gland Carcinoma of the Oropharynx: A Population-Based Analysis of 1426 Patients. ( 28971745 )
2018
26
Survival Outcome of Intermediate-Grade Salivary Gland Carcinoma. ( 29151106 )
2018
27
A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. ( 29211833 )
2018
28
Combined androgen blockade for salivary gland carcinoma. ( 29233558 )
2018
29
Retraction: Genome-wide association study identifies common genetic variants associated with salivary gland carcinoma and its subtypes by Xu L, Tang H, Chen DW, El-Naggar AK, Wei P, Sturgis EM. ( 29406587 )
2018
30
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. ( 29462123 )
2018
31
Health-related quality of life in patients with major salivary gland carcinoma. ( 29478078 )
2018
32
Prognostic significance and optimal candidates of primary tumor resection in major salivary gland carcinoma patients with distant metastases at initial presentation: A population-based study. ( 29496064 )
2018
33
Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target. ( 29863801 )
2018
34
Retraction: Genetic Variants in DNA Double-Strand Break Repair Genes and Risk of Salivary Gland Carcinoma: A Case-Control Study. ( 29928030 )
2018
35
Androgen deprivation therapy for metastatic salivary gland cancer. ( 30127038 )
2018
36
Insurance Status and Survival of Patients with Salivary Gland Cancer. ( 30324868 )
2018
37
Potential therapeutic effects of induced pluripotent stem cells on induced salivary gland cancer in experimental rats. ( 30338701 )
2018
38
The number and ratio of positive lymph nodes are independent prognostic factors for patients with major salivary gland cancer: Results from the surveillance, epidemiology, and End Results dataset. ( 30472214 )
2018
39
Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer. ( 30558663 )
2018
40
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). ( 28102887 )
2017
41
Androgen Receptor Signaling in Salivary Gland Cancer. ( 28208703 )
2017
42
Nomograms for predicting long-term overall survival and cancer-specific survival in patients with major salivary gland cancer: a population-based study. ( 28160551 )
2017
43
Effective nasal mask ventilation of a difficult airway in a patient with advanced salivary gland cancer. ( 28494881 )
2017
44
The rising incidence of major salivary gland cancer in the United States. ( 28346649 )
2017
45
Develop and validation a nomogram to predict the recurrent probability in patients with major salivary gland cancer. ( 28819427 )
2017
46
Increased SOX2 expression in salivary gland carcinoma ex pleomorphic adenoma progression: an association with adverse outcome. ( 28842747 )
2017
47
A Case-Control Study of Risk Factors for Salivary Gland Cancer in Canada. ( 28133481 )
2017
48
Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade. ( 28401485 )
2017
49
Heterogeneous impact of smoking on major salivary gland cancer according to histopathological subtype: A case-control study. ( 28881386 )
2017
50
Immunohistochemical and molecular profile of salivary gland cancer in children. ( 28139061 )
2017
Sources

Variations for Salivary Gland Carcinoma

About this section

Cosmic variations for Salivary Gland Carcinoma:

9 (show top 50) (show all 376)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6845145 ZFHX3 salivary gland,major,carcinoma,NS c.8617G>A p.E2873K 16:72794065-72794065 0
2 COSM6979379 TSHR salivary gland,major,carcinoma,NS c.1376C>T p.A459V 14:81143434-81143434 0
3 COSM6983845 TSC2 salivary gland,major,carcinoma,NS c.2276G>A p.R759K 16:2072904-2072904 0
4 COSM6939530 TSC2 salivary gland,major,carcinoma,NS c.2402C>T p.A801V 16:2074246-2074246 0
5 COSM6939527 TSC1 salivary gland,major,carcinoma,NS c.2684T>A p.V895D 9:132897552-132897552 0
6 COSM43878 TP53 salivary gland,major,carcinoma,NS c.427G>A p.V143M 17:7675185-7675185 0
7 COSM10662 TP53 salivary gland,major,carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 0
8 COSM307275 TP53 salivary gland,major,carcinoma,NS c.96+1G>T p.? 17:7676381-7676381 0
9 COSM10905 TP53 salivary gland,major,carcinoma,NS c.451C>T p.P151S 17:7675161-7675161 0
10 COSM43951 TP53 salivary gland,major,carcinoma,NS c.643A>G p.S215G 17:7674888-7674888 0
11 COSM10659 TP53 salivary gland,major,carcinoma,NS c.817C>T p.R273C 17:7673803-7673803 0
12 COSM10705 TP53 salivary gland,major,carcinoma,NS c.586C>T p.R196* 17:7674945-7674945 0
13 COSM10648 TP53 salivary gland,major,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 0
14 COSM43931 TP53 salivary gland,major,carcinoma,NS c.523C>A p.R175S 17:7675089-7675089 0
15 COSM11354 TP53 salivary gland,major,carcinoma,NS c.991C>T p.Q331* 17:7673537-7673537 0
16 COSM43680 TP53 salivary gland,major,carcinoma,NS c.523C>T p.R175C 17:7675089-7675089 0
17 COSM44119 TP53 salivary gland,major,carcinoma,NS c.483C>T p.A161A 17:7675129-7675129 0
18 COSM10758 TP53 salivary gland,major,carcinoma,NS c.659A>G p.Y220C 17:7674872-7674872 0
19 COSM10786 TP53 salivary gland,major,carcinoma,NS c.949C>T p.Q317* 17:7673579-7673579 0
20 COSM10777 TP53 salivary gland,major,carcinoma,NS c.715A>G p.N239D 17:7674248-7674248 0
21 COSM6930930 TENT5C salivary gland,major,carcinoma,NS c.702G>C p.K234N 1:117623570-117623570 0
22 COSM6983859 TCF3 salivary gland,major,carcinoma,NS c.173C>T p.S58F 19:1632378-1632378 0
23 COSM6983856 SUZ12 salivary gland,major,carcinoma,NS c.766C>T p.R256C 17:31975656-31975656 0
24 COSM6951891 STK40 salivary gland,major,carcinoma,NS c.97G>T p.G33* 1:36361236-36361236 0
25 COSM6951889 STK40 salivary gland,major,carcinoma,NS c.97G>T p.G33* 1:36361236-36361236 0
26 COSM6939534 STAG2 salivary gland,major,carcinoma,NS c.2405T>G p.I802S 23:124071195-124071195 0
27 COSM6920823 STAG2 salivary gland,major,carcinoma,NS c.1808G>A p.G603E 23:124063192-124063192 0
28 COSM6924542 SPEN salivary gland,major,carcinoma,NS c.1648C>T p.R550C 1:15920882-15920882 0
29 COSM6939532 SOX9 salivary gland,major,carcinoma,NS c.1457T>A p.V486D 17:72124314-72124314 0
30 COSM6983831 SOX17 salivary gland,major,carcinoma,NS c.1181C>T p.A394V 8:54459931-54459931 0
31 COSM2769709 SMO salivary gland,major,carcinoma,NS c.1513C>T p.P505S 7:129210409-129210409 0
32 COSM6939526 SMO salivary gland,major,carcinoma,NS c.385G>C p.V129L 7:129203437-129203437 0
33 COSM1226761 SMARCA4 salivary gland,major,carcinoma,NS c.3967C>T p.R1323C 19:11034929-11034929 0
34 COSM6941870 SMARCA4 salivary gland,major,carcinoma,NS c.848C>G p.P283R 19:10986992-10986992 0
35 COSM6964890 SH2B3 salivary gland,major,carcinoma,NS c.241G>A p.D81N 12:111418386-111418386 0
36 COSM6951921 SH2B3 salivary gland,major,carcinoma,NS c.1226G>A p.G409E 12:111447534-111447534 0
37 COSM1159845 SF3B1 salivary gland,major,carcinoma,NS c.2324G>A p.R775Q 2:197401788-197401788 0
38 COSM5891771 SETD2 salivary gland,major,carcinoma,NS c.3994C>T p.P1332S 3:47084277-47084277 0
39 COSM5995773 SDHA salivary gland,major,carcinoma,NS c.724G>A p.G242R 5:228287-228287 0
40 COSM4991131 RPTOR salivary gland,major,carcinoma,NS c.3788C>T p.P1263L 17:80962556-80962556 0
41 COSM3451453 RPS6KA4 salivary gland,major,carcinoma,NS c.967C>T p.R323C 11:64365361-64365361 0
42 COSM6983822 ROS1 salivary gland,major,carcinoma,NS c.2878G>A p.G960R 6:117365676-117365676 0
43 COSM5610508 ROS1 salivary gland,major,carcinoma,NS c.5794G>A p.E1932K 6:117320014-117320014 0
44 COSM6983819 ROS1 salivary gland,major,carcinoma,NS c.5211A>T p.E1737D 6:117337209-117337209 0
45 COSM3726697 RNF43 salivary gland,major,carcinoma,NS c.434G>A p.R145Q 17:58363542-58363542 0
46 COSM6983815 RICTOR salivary gland,major,carcinoma,NS c.712C>T p.P238S 5:38981908-38981908 0
47 COSM1644939 RB1 salivary gland,major,carcinoma,NS c.1817A>G p.Y606C 13:48456206-48456206 0
48 COSM6913929 RASA1 salivary gland,major,carcinoma,NS c.2603+2T>A p.? 5:87379852-87379852 0
49 COSM6910894 RASA1 salivary gland,major,carcinoma,NS c.3026T>G p.L1009R 5:87389493-87389493 0
50 COSM6951920 RAD52 salivary gland,major,carcinoma,NS c.761C>G p.T254R 12:916448-916448 0
Sources

Expression for Salivary Gland Carcinoma

About this section
Search GEO for disease gene expression data for Salivary Gland Carcinoma.
Sources

Pathways for Salivary Gland Carcinoma

About this section

Pathways related to Salivary Gland Carcinoma according to KEGG:

38
# Name Kegg Source Accession
1 Notch signaling pathway hsa04330

Pathways related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 38
Show member pathways
 12.77 EGFR HGF KIT MAML2 MDM2 MET
2
Gastric cancer 38
Show member pathways
 12.59 CDKN2A EGFR HGF KIT MET
3
Glioma 38
Show member pathways
 12.53 CDKN2A EGFR HGF MDM2 MET
4
Downstream signaling events of B Cell Receptor (BCR) 67
Show member pathways
 12.53 EGFR HGF KIT MDM2 MET
5
ErbB signaling pathway 1 38
Show member pathways
 12.42 EGFR HGF MDM2 MET
6
MicroRNAs in cancer 38
12.35 CDKN2A EGFR MDM2 MET
7
Pathways in cancer 38
12.16 CDKN2A EGFR HGF KIT MDM2 MET
8
Proteoglycans in cancer 38
12.08 EGFR HGF MDM2 MET
9
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.75 HGF ISL1 MET SOX2
10
Listeria monocytogenes entry into host cells 67
Show member pathways
 11.7 EGFR HGF MET
11
Direct p53 effectors 1
11.68 EGFR HGF MDM2 MET
12
Bladder cancer 38 1
11.59 CDKN2A EGFR MDM2
13
Central carbon metabolism in cancer 38
11.5 EGFR KIT MET
14
Cardiac Progenitor Differentiation 1
11.33 ISL1 KIT SOX2
15
Signaling events mediated by TCPTP 1
Show member pathways
 11.2 EGFR HGF MET
16
Stabilization and expansion of the E-cadherin adherens junction 1
11.15 EGFR HGF MET
17
Arf6 signaling events 1
10.86 EGFR HGF MET
18
Syndecan-1-mediated signaling events 1
10.81 HGF MET
19
Extracellular vesicle-mediated signaling in recipient cells 1
10.28 EGFR HGF MET
Sources

GO Terms for Salivary Gland Carcinoma

About this section

Cellular components related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.85 ALKBH3 CDKN2A CPSF4 CRTC1 CRTC3 ISL1
2 cytoplasm GO:0005737 9.77 ALKBH3 CDKN2A CRTC1 CRTC3 CYLD EGFR
3 nucleus GO:0005634 9.5 ALKBH1 ALKBH3 CDKN2A CPSF4 CRTC1 CRTC3

Biological processes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.89 ALKBH1 EGFR ISL1 SOX2
2 viral process GO:0016032 9.83 CPSF4 CRTC1 CRTC3 KRT7 MDM2
3 MAPK cascade GO:0000165 9.8 EGFR HGF KIT MET
4 regulation of gene expression GO:0010468 9.78 ALKBH1 ISL1 MDM2 SOX2
5 negative regulation of apoptotic process GO:0043066 9.76 EGFR HGF MDM2
6 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.75 EGFR KIT MET
7 liver development GO:0001889 9.72 EGFR HGF MET
8 peptidyl-tyrosine phosphorylation GO:0018108 9.71 EGFR HGF KIT MET
9 positive regulation of protein kinase B signaling GO:0051897 9.67 EGFR HGF KIT MET
10 endocardial cushion morphogenesis GO:0003203 9.61 ISL1 MDM2
11 positive regulation of CREB transcription factor activity GO:0032793 9.6 CRTC1 CRTC3
12 hepatocyte growth factor receptor signaling pathway GO:0048012 9.57 HGF MET
13 tongue development GO:0043586 9.56 EGFR KIT
14 DNA dealkylation involved in DNA repair GO:0006307 9.54 ALKBH1 ALKBH3
15 locomotor rhythm GO:0045475 9.52 MC3R MTA1
16 somatic stem cell division GO:0048103 9.51 CDKN2A KIT
17 positive chemotaxis GO:0050918 9.5 ALKBH1 HGF MET
18 amyloid fibril formation GO:1990000 9.46 CDKN2A MDM2
19 positive regulation of transcription by RNA polymerase II GO:0045944 9.32 CDKN2A CRTC1 CRTC3 EGFR HGF ISL1
20 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.26 HGF MET
21 phosphatidylinositol phosphorylation GO:0046854 9.26 EGFR HGF KIT MET
22 positive regulation of MAPK cascade GO:0043410 9.16 KIT SOX2

Molecular functions related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.46 EGFR HGF KIT MET
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 EGFR KIT MET
3 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors GO:0016706 9.37 ALKBH1 ALKBH3
4 cAMP response element binding protein binding GO:0008140 9.32 CRTC1 CRTC3
5 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.26 EGFR HGF KIT MET
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.92 EGFR HGF KIT MET
Sources

Sources for Salivary Gland Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....